It is a first molecular target medication developed by AstraZeneca for the treatment of NSCLC.12 Compared with traditional chemotherapy drugs, Gefitinib, a targeted drug that regulates tumor pathogenesis at the molecular level of cell receptor and value-added regulation, can significantly prolong the disease-free survival of patients with EGFR mutation positive.13 This evidence concerns the gene EGFR and non-small cell lung carcinoma.